ArticleFrontiers in medicine2026
Case Report: Primary myelofibrosis presenting with non-cirrhotic portal hypertension and initially misdiagnosed as cirrhosis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary myelofibrosis (PMF) is a rare cause of non-cirrhotic portal hypertension (NCPH). Because the clinical manifestations of NCPH often resemble those of cirrhosis-related portal hypertension, it is frequently misdiagnosed as cirrhosis in clinical practice. Herein, we report the case of a patient who presented with long-standing fatigue, progressive anemia, splenomegaly, and manifestations of portal hypertension, and was initially considered to have cirrhosis-related portal hypertension; a subsequent hematologic evaluation established the diagnosis of PMF. The patient then received standard ruxolitinib-based therapy, with improvement in spleen size and related symptoms. This case highlights that when the degree of liver injury is discordant with the severity of portal hypertension, particularly in the presence of hematologic abnormalities that cannot be fully explained by hypersplenism, potential underlying hematologic causes should be actively investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.